| Basics |
Gilead Sciences, Inc.
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
|
| IPO Date: |
January 3, 1994 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$153.1B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.74 | 1.13%
|
| Avg Daily Range (30 D): |
$1.59 | 1.34%
|
| Avg Daily Range (90 D): |
$1.33 | 1.15%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
7.32M |
| Avg Daily Volume (30 D): |
5.61M |
| Avg Daily Volume (90 D): |
4.97M |
| Trade Size |
| Avg Trade Size (Sh.): |
138 |
| Avg Trade Size (Sh.) (30 D): |
59 |
| Avg Trade Size (Sh.) (90 D): |
60 |
| Institutional Trades |
| Total Inst.Trades: |
121,873 |
| Avg Inst. Trade: |
$5.29M |
| Avg Inst. Trade (30 D): |
$12.59M |
| Avg Inst. Trade (90 D): |
$15.4M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
21 |
| Market Closing Trades |
| Avg Closing Trade: |
$55.69M |
| Avg Closing Trade (30 D): |
$144.81M |
| Avg Closing Trade (90 D): |
$134.91M |
| Avg Closing Volume: |
845.62K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$6.5
|
$2.46
|
$1.57
|
|
Diluted EPS
|
$6.46
|
$2.43
|
$1.56
|
|
Revenue
|
$ 29.09B
|
$ 7.77B
|
$ 7.08B
|
|
Gross Profit
|
$ 22.9B
|
$ 6.2B
|
$ 5.58B
|
|
Net Income / Loss
|
$ 8.11B
|
$ 3.05B
|
$ 1.96B
|
|
Operating Income / Loss
|
$ 10.49B
|
$ 3.33B
|
$ 2.47B
|
|
Cost of Revenue
|
$ 6.19B
|
$ 1.57B
|
$ 1.5B
|
|
Net Cash Flow
|
$ 2.29B
|
$ 2.19B
|
$ -2783M
|
|
PE Ratio
|
19.48
|
|
|
| Splits |
|
Jan 28, 2013:
2:1
|
|
Jun 25, 2007:
2:1
|
|
Sep 07, 2004:
2:1
|
|
Mar 08, 2002:
2:1
|
|
Feb 22, 2001:
2:1
|
|
|
|
